Faron Pharmaceuticals Oy has announced the approval of the terms and conditions of 832,934 warrants, pursuant to the warrantholder agreement with IPF. The maximum total number of warrants to be granted under the agreement is 1,500,000, with each warrant entitling its holder to subscribe for one new share in the Company. Additionally, the number of warrants issued to IPF may be increased upon agreed adjustment events. The strike price of the warrants is currently EUR 1.50 and will be adjusted to any lower subsequent subscription price of shares in any future share issue.
The Company has resolved to issue an additional 53,570 warrants to IPF based on the placement of 3,200,298 newly issued treasury shares at the issue price of EUR 1.50. The Company will separately publish an announcement on the issuance of any of the additional warrants.
For more information, investors can contact various individuals and firms associated with Faron Pharmaceuticals, including LifeSci Advisors, ICR Consilium, Cairn Financial Advisers LLP, Peel Hunt LLP, and Sisu Partners Oy.
Faron Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments.